

## **The Impact of Ageing on Dopamine Transporter Imaging**

Rudolf A. Werner<sup>1,2</sup>; Charles Marcus<sup>1</sup>; Sara Sheikhabaei<sup>1</sup>; Takahiro Higuchi<sup>2,3</sup>; Lilja B. Solnes<sup>1</sup>; Steven P. Rowe<sup>1</sup>; Andreas K. Buck<sup>2</sup>; Constantin Lapa<sup>2</sup>; Mehrbod S. Javadi<sup>1</sup>


1. Johns Hopkins University School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, United States;
2. Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany;
3. Department of Biomedical Imaging, National Cardiovascular and Cerebral Research Center, Suita, Japan.

**Objectives:** The nigrostriatal and dopaminergic system is one of the most age-sensitive neurotransmitters. Given the more widespread use of DaT-SPECT outside controlled clinical trials, we aimed to explore the age-induced loss of dopamine transporter binding in normal subjects on a larger scale.

**Material and Methods:** In a mono-centric setting, 382 patients with clinically uncertain parkinsonian syndrome underwent DaT-SPECT after IV administration of 3-5 mCi <sup>123</sup>I-loflupane. Two experienced nuclear medicine physicians, blinded to the clinical status and diagnosis, performed a visual evaluation of all scans independently. Binary reporting was performed by qualitative analysis of tracer uptake and morphology within the putamen and caudate in each hemisphere. For exploration of age-dependent loss of DaT binding, only patients with normal results by both observers and the findings of a fully automatic semiquantitative evaluation method (Xeleris, 4.0, GE Healthcare) were analyzed. Pearson correlation and linear regression analysis were performed to explore the effect of age on <sup>123</sup>I-loflupane binding ratio.

**Results:** Of the 382 investigated subjects, 133 patients (34.8%, 66 females, median age, 63y, range, 41y-80y) were rated normal by both observers (distribution over decades: {41-50y: n=18}; {51-60y: n=30}; {61-70y: n=49}; {71-80y: n=36}). Pearson correlation showed a significant inverse correlation between age and <sup>123</sup>I-ioflupane binding ratio in the striatum (correlation coefficient -0.38; p<0.001), putamen (correlation coefficient -0.39; P<0.001) and caudate (correlation coefficient -0.3; P<0.001). Linear regression of all investigated subjects demonstrated an average decrease of 0.19 per decade in the striatal binding ratio, within the age group of 41-80 years (6.6% loss {95% CI= 3.7- 9.5%}, per decade).

**Conclusions:** Investigating a potential age-induced loss of dopamine transporter binding on a larger scale, a 6.6% decrease per decade of life in striatal dopamine transporter binding was recorded. Further studies targeting towards functional consequences of age-induced dopamine transporter binding loss might pave the way for a deeper understanding in motor impairment in the elderly population.



Correlation between striatal binding ratio and age (in years) in 133 subjects rated normal by two observers (correlation coefficient -0.38;  $P < 0.001$ ). An average decrease of 6.6% per decade in the striatal binding ratio was recorded.

Research Support: This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 701983.

*This research was originally published in JNM. Rudolf A. Werner, Charles Marcus, Sara Sheikhabaei, Takahiro Higuchi, Lilja B. Solnes, Steven P. Rowe, Andreas K. Buck, Constantin Lapa, Mehrbod S. Javadi. The Impact of Ageing on Dopamine Transporter Imaging. J Nucl Med. May 1, 2018; vol. 59 no. supplement 1:1646. © SNMMI.*